Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Inhibition of Hepatotoxicity by a LXR Inverse Agonist in a Model of Alcoholic Liver Disease.

Sengupta M, Griffett K, Flaveny CA, Burris TP.

ACS Pharmacol Transl Sci. 2018 Sep 14;1(1):50-60. doi: 10.1021/acsptsci.8b00003. Epub 2018 Jul 25.

2.

SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome.

Reitz CJ, Alibhai FJ, Khatua TN, Rasouli M, Bridle BW, Burris TP, Martino TA.

Commun Biol. 2019 Oct 3;2:353. doi: 10.1038/s42003-019-0595-z. eCollection 2019.

3.

Circadian rhythm-dependent and circadian rhythm-independent impacts of the molecular clock on type 3 innate lymphoid cells.

Wang Q, Robinette ML, Billon C, Collins PL, Bando JK, Fachi JL, Sécca C, Porter SI, Saini A, Gilfillan S, Solt LA, Musiek ES, Oltz EM, Burris TP, Colonna M.

Sci Immunol. 2019 Oct 4;4(40). pii: eaay7501. doi: 10.1126/sciimmunol.aay7501.

PMID:
31586012
4.

The nuclear receptor REV-ERBα modulates Th17 cell-mediated autoimmune disease.

Chang C, Loo CS, Zhao X, Solt LA, Liang Y, Bapat SP, Cho H, Kamenecka TM, Leblanc M, Atkins AR, Yu RT, Downes M, Burris TP, Evans RM, Zheng Y.

Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18528-18536. doi: 10.1073/pnas.1907563116. Epub 2019 Aug 27.

5.

A synthesis strategy for tetracyclic terpenoids leads to agonists of ERβ.

Kim WS, Shalit ZA, Nguyen SM, Schoepke E, Eastman A, Burris TP, Gaur AB, Micalizio GC.

Nat Commun. 2019 Jun 4;10(1):2448. doi: 10.1038/s41467-019-10415-6.

6.

Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.

Roby DA, Ruiz F, Kermath BA, Voorhees JR, Niehoff M, Zhang J, Morley JE, Musiek ES, Farr SA, Burris TP.

PLoS One. 2019 Apr 11;14(4):e0215004. doi: 10.1371/journal.pone.0215004. eCollection 2019.

7.

Circadian clock protein Rev-erbα regulates neuroinflammation.

Griffin P, Dimitry JM, Sheehan PW, Lananna BV, Guo C, Robinette ML, Hayes ME, Cedeño MR, Nadarajah CJ, Ezerskiy LA, Colonna M, Zhang J, Bauer AQ, Burris TP, Musiek ES.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5102-5107. doi: 10.1073/pnas.1812405116. Epub 2019 Feb 21.

8.

Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold.

Goher SS, Griffett K, Hegazy L, Elagawany M, Arief MMH, Avdagic A, Banerjee S, Burris TP, Elgendy B.

Bioorg Med Chem Lett. 2019 Feb 1;29(3):449-453. doi: 10.1016/j.bmcl.2018.12.025. Epub 2018 Dec 15.

PMID:
30587446
9.

Doubled lifespan and patient-like pathologies in progeria mice fed high-fat diet.

Kreienkamp R, Billon C, Bedia-Diaz G, Albert CJ, Toth Z, Butler AA, McBride-Gagyi S, Ford DA, Baldan A, Burris TP, Gonzalo S.

Aging Cell. 2019 Feb;18(1):e12852. doi: 10.1111/acel.12852. Epub 2018 Dec 12.

10.

RORγ regulates the NLRP3 inflammasome.

Billon C, Murray MH, Avdagic A, Burris TP.

J Biol Chem. 2019 Jan 4;294(1):10-19. doi: 10.1074/jbc.AC118.002127. Epub 2018 Nov 19.

PMID:
30455347
11.

Recent Advances in the Medicinal Chemistry of Liver X Receptors.

El-Gendy BEM, Goher SS, Hegazy LS, Arief MMH, Burris TP.

J Med Chem. 2018 Dec 27;61(24):10935-10956. doi: 10.1021/acs.jmedchem.8b00045. Epub 2018 Jul 30. Review.

PMID:
30004226
12.

Corrigendum to "Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain" [GENE 655 (2018) 1-12].

Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im HJ.

Gene. 2019 Jan 5;680:105. doi: 10.1016/j.gene.2018.06.013. Epub 2018 Jun 12. No abstract available.

PMID:
29890121
13.

Distinct roles for REV-ERBα and REV-ERBβ in oxidative capacity and mitochondrial biogenesis in skeletal muscle.

Amador A, Campbell S, Kazantzis M, Lan G, Burris TP, Solt LA.

PLoS One. 2018 May 3;13(5):e0196787. doi: 10.1371/journal.pone.0196787. eCollection 2018.

14.

Pharmacological targeting of the mammalian clock reveals a novel analgesic for osteoarthritis-induced pain.

Das V, Kc R, Li X, Varma D, Qiu S, Kroin JS, Forsyth CB, Keshavarzian A, van Wijnen AJ, Park TJ, Stein GS, O-Sullivan I, Burris TP, Im HJ.

Gene. 2018 May 20;655:1-12. doi: 10.1016/j.gene.2018.02.048. Epub 2018 Feb 20. Erratum in: Gene. 2019 Jan 5;680:105.

PMID:
29474860
15.

REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.

Amador A, Kamenecka TM, Solt LA, Burris TP.

Biochem Pharmacol. 2018 Apr;150:1-8. doi: 10.1016/j.bcp.2018.01.009. Epub 2018 Jan 23.

PMID:
29355503
16.

Adropin: An endocrine link between the biological clock and cholesterol homeostasis.

Ghoshal S, Stevens JR, Billon C, Girardet C, Sitaula S, Leon AS, Rao DC, Skinner JS, Rankinen T, Bouchard C, Nuñez MV, Stanhope KL, Howatt DA, Daugherty A, Zhang J, Schuelke M, Weiss EP, Coffey AR, Bennett BJ, Sethupathy P, Burris TP, Havel PJ, Butler AA.

Mol Metab. 2018 Feb;8:51-64. doi: 10.1016/j.molmet.2017.12.002. Epub 2017 Dec 30.

17.

Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice.

Pourcet B, Zecchin M, Ferri L, Beauchamp J, Sitaula S, Billon C, Delhaye S, Vanhoutte J, Mayeuf-Louchart A, Thorel Q, Haas JT, Eeckhoute J, Dombrowicz D, Duhem C, Boulinguiez A, Lancel S, Sebti Y, Burris TP, Staels B, Duez HM.

Gastroenterology. 2018 Apr;154(5):1449-1464.e20. doi: 10.1053/j.gastro.2017.12.019. Epub 2017 Dec 24.

18.

Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle.

Welch RD, Billon C, Valfort AC, Burris TP, Flaveny CA.

Sci Rep. 2017 Dec 7;7(1):17142. doi: 10.1038/s41598-017-17496-7.

19.

REV-ERBα ameliorates heart failure through transcription repression.

Zhang L, Zhang R, Tien CL, Chan RE, Sugi K, Fu C, Griffin AC, Shen Y, Burris TP, Liao X, Jain MK.

JCI Insight. 2017 Sep 7;2(17). pii: 95177. doi: 10.1172/jci.insight.95177. eCollection 2017 Sep 7.

20.

Metabolic Characterization of a Novel RORα Knockout Mouse Model without Ataxia.

Billon C, Sitaula S, Burris TP.

Front Endocrinol (Lausanne). 2017 Jul 11;8:141. doi: 10.3389/fendo.2017.00141. eCollection 2017.

21.

Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome.

Welch RD, Guo C, Sengupta M, Carpenter KJ, Stephens NA, Arnett SA, Meyers MJ, Sparks LM, Smith SR, Zhang J, Burris TP, Flaveny CA.

Mol Metab. 2017 May 19;6(7):703-714. doi: 10.1016/j.molmet.2017.05.001. eCollection 2017 Jul.

22.

Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and induction of antitumor CD8+ T-cell activity.

Gu T, De Jesus M, Gallagher HC, Burris TP, Egilmez NK.

Oncoimmunology. 2017 Apr 20;6(6):e1319027. doi: 10.1080/2162402X.2017.1319027. eCollection 2017.

23.

Targeting Th17-IL-17 Pathway in Prevention of Micro-Invasive Prostate Cancer in a Mouse Model.

Zhang Q, Liu S, Ge D, Cunningham DM, Huang F, Ma L, Burris TP, You Z.

Prostate. 2017 Jun;77(8):888-899. doi: 10.1002/pros.23343. Epub 2017 Feb 27.

24.

Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease.

Alibhai FJ, LaMarre J, Reitz CJ, Tsimakouridze EV, Kroetsch JT, Bolz SS, Shulman A, Steinberg S, Burris TP, Oudit GY, Martino TA.

J Mol Cell Cardiol. 2017 Apr;105:24-37. doi: 10.1016/j.yjmcc.2017.01.008. Epub 2017 Feb 20.

25.

Rev-erb regulation of cholesterologenesis.

Sitaula S, Zhang J, Ruiz F, Burris TP.

Biochem Pharmacol. 2017 May 1;131:68-77. doi: 10.1016/j.bcp.2017.02.006. Epub 2017 Feb 15.

PMID:
28213272
26.

Nuclear receptors: PPARα ligands make memories.

Burris TP.

Nat Chem Biol. 2016 Nov 15;12(12):993-994. doi: 10.1038/nchembio.2241. No abstract available.

PMID:
27846207
27.

Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation.

Billon C, Sitaula S, Burris TP.

Mol Metab. 2016 Jul 25;5(10):997-1005. doi: 10.1016/j.molmet.2016.07.001. eCollection 2016 Oct.

28.

Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease.

Griffett K, Burris TP.

Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428. doi: 10.1016/j.bbrc.2016.09.036. Epub 2016 Sep 25.

29.

Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.

Amador A, Huitron-Resendiz S, Roberts AJ, Kamenecka TM, Solt LA, Burris TP.

PLoS One. 2016 Sep 7;11(9):e0162452. doi: 10.1371/journal.pone.0162452. eCollection 2016.

30.

Correction: Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.

Amador A, Wang Y, Banerjee S, Kamenecka TM, Solt LA, Burris TP.

PLoS One. 2016 May 19;11(5):e0156367. doi: 10.1371/journal.pone.0156367. eCollection 2016.

31.

Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.

Amador A, Wang Y, Banerjee S, Kameneka TM, Solt LA, Burris TP.

PLoS One. 2016 Mar 10;11(3):e0151014. doi: 10.1371/journal.pone.0151014. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0156367.

32.

Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism.

Wang Y, Billon C, Walker JK, Burris TP.

ACS Chem Neurosci. 2016 Feb 17;7(2):143-8. doi: 10.1021/acschemneuro.5b00159. Epub 2015 Dec 3.

33.

Segregation of Clock and Non-Clock Regulatory Functions of REV-ERB.

Butler AA, Burris TP.

Cell Metab. 2015 Aug 4;22(2):197-8. doi: 10.1016/j.cmet.2015.07.014.

34.

Th17 cells in Type 1 diabetes: a future perspective.

Solt LA, Burris TP.

Diabetes Manag (Lond). 2015 Jul;5(4):247-250. No abstract available.

35.

Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Flaveny CA, Griffett K, El-Gendy Bel-D, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP.

Cancer Cell. 2015 Jul 13;28(1):42-56. doi: 10.1016/j.ccell.2015.05.007. Epub 2015 Jun 25.

36.

Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells.

Wang Y, Kojetin D, Burris TP.

Biochem Pharmacol. 2015 Aug 15;96(4):315-22. doi: 10.1016/j.bcp.2015.06.010. Epub 2015 Jun 12.

37.

SIRT1 in the Ventromedial Hypothalamus: A Nutrient Sensor Input Into the Internal Timekeeper.

Girardet C, Burris TP, Butler AA.

Endocrinology. 2015 Jun;156(6):1936-8. doi: 10.1210/en.2015-1346. No abstract available.

38.

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis.

Griffett K, Welch RD, Flaveny CA, Kolar GR, Neuschwander-Tetri BA, Burris TP.

Mol Metab. 2015 Feb 9;4(4):353-7. doi: 10.1016/j.molmet.2015.01.009. eCollection 2015 Apr.

39.

Suppression of atherosclerosis by synthetic REV-ERB agonist.

Sitaula S, Billon C, Kamenecka TM, Solt LA, Burris TP.

Biochem Biophys Res Commun. 2015 May 8;460(3):566-71. doi: 10.1016/j.bbrc.2015.03.070. Epub 2015 Mar 20.

40.

Design and synthesis of a novel series of [1-(4-hydroxy-benzyl)-1H-indol-5-yloxy]-acetic acid compounds as potent, selective, thyroid hormone receptor β agonists.

Burkholder TP, Cunningham BE, Clayton JR, Lander PA, Brown ML, Doti RA, Durst GL, Montrose-Rafizadeh C, King C, Osborne HE, Amos RM, Zink RW, Stramm LE, Burris TP, Cardona G, Konkol DL, Reidy C, Christe ME, Genin MJ.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1377-80. doi: 10.1016/j.bmcl.2015.02.062. Epub 2015 Mar 3.

PMID:
25752984
41.

ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes.

Solt LA, Banerjee S, Campbell S, Kamenecka TM, Burris TP.

Endocrinology. 2015 Mar;156(3):869-81. doi: 10.1210/en.2014-1677. Epub 2015 Jan 5.

42.

Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour.

Banerjee S, Wang Y, Solt LA, Griffett K, Kazantzis M, Amador A, El-Gendy BM, Huitron-Resendiz S, Roberts AJ, Shin Y, Kamenecka TM, Burris TP.

Nat Commun. 2014 Dec 23;5:5759. doi: 10.1038/ncomms6759.

43.

The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2.

Guo C, Li Y, Gow CH, Wong M, Zha J, Yan C, Liu H, Wang Y, Burris TP, Zhang J.

J Biol Chem. 2015 Feb 6;290(6):3666-79. doi: 10.1074/jbc.M114.598797. Epub 2014 Dec 17.

44.

Clock genes, pancreatic function, and diabetes.

Vieira E, Burris TP, Quesada I.

Trends Mol Med. 2014 Dec;20(12):685-93. doi: 10.1016/j.molmed.2014.10.007. Epub 2014 Nov 5. Review.

45.

International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands.

Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ.

Pharmacol Rev. 2014 Oct;66(4):918-47. doi: 10.1124/pr.114.008862.

PMID:
25026896
46.

Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice.

Richard AJ, Burris TP, Sanchez-Infantes D, Wang Y, Ribnicky DM, Stephens JM.

Nutrition. 2014 Jul-Aug;30(7-8 Suppl):S31-6. doi: 10.1016/j.nut.2014.02.013. Epub 2014 Mar 12.

47.

Artemisia scoparia enhances adipocyte development and endocrine function in vitro and enhances insulin action in vivo.

Richard AJ, Fuller S, Fedorcenco V, Beyl R, Burris TP, Mynatt R, Ribnicky DM, Stephens JM.

PLoS One. 2014 Jun 10;9(6):e98897. doi: 10.1371/journal.pone.0098897. eCollection 2014.

48.

Structure of REV-ERBβ ligand-binding domain bound to a porphyrin antagonist.

Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Wang Y, Burris TP, Kojetin DJ.

J Biol Chem. 2014 Jul 18;289(29):20054-66. doi: 10.1074/jbc.M113.545111. Epub 2014 May 28.

49.

An alternate binding site for PPARγ ligands.

Hughes TS, Giri PK, de Vera IM, Marciano DP, Kuruvilla DS, Shin Y, Blayo AL, Kamenecka TM, Burris TP, Griffin PR, Kojetin DJ.

Nat Commun. 2014 Apr 7;5:3571. doi: 10.1038/ncomms4571.

50.

REV-ERB and ROR nuclear receptors as drug targets.

Kojetin DJ, Burris TP.

Nat Rev Drug Discov. 2014 Mar;13(3):197-216. doi: 10.1038/nrd4100. Review.

Supplemental Content

Loading ...
Support Center